Literature DB >> 2969804

Phorbol 12,13-dibutyrate and mitogens increase fructose 2,6-bisphosphate in lymphocytes. Comparison of lymphocyte and rat-liver 6-phosphofructo-2-kinase.

L Bosca1, M Mojena, J M Diaz-Guerra, C Marquez.   

Abstract

The influence of tumour promoters and growth factors on glycolysis and on fructose-2,6-bisphosphate concentration was studied in isolated mouse spleen lymphocytes and in purified B-cells. The intracellular concentration of fructose 2,6-bisphosphate and the rate of lactate release were increased 2-3-fold in spleen lymphocytes exposed to active phorbol esters, mitogenic lectins, interleukin 4 or lipopolysaccharide. The maximal effect was observed after 1 h of exposure. In these cells hexose 6-phosphates increased 2-fold and 6-phosphofructo-2-kinase activity remained unchanged after treatment with phorbol 12,13-dibutyrate or with lectins. Exposure of B-cells to phorbol 12,13-dibutyrate, interleukin 4 or lipopolysaccharide increased the glycolytic flux and the concentration of fructose 2,6-bisphosphate without relation to their mitogenic activity. Lymphocytes and rat liver 6-phosphofructo-2-kinase were partially purified using the same procedure. The lymphocyte enzyme was not inhibited by sn-glycerol 3-phosphate in contrast to the potent inhibition observed in liver. Treatment of both enzymes with the catalytic subunit of the cyclic-AMP-dependent protein kinase failed to inactivate 6-phosphofructo-2-kinase from lymphocytes. These differences suggest that lymphocytes and liver contain different forms of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969804     DOI: 10.1111/j.1432-1033.1988.tb14199.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

Review 1.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis.

Authors:  Mark H Rider; Luc Bertrand; Didier Vertommen; Paul A Michels; Guy G Rousseau; Louis Hue
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

2.  Protein kinase C activators selectively inhibit insulin-stimulated system A transport activity in skeletal muscle at a post-receptor level.

Authors:  A Gumà; M Camps; M Palacín; X Testar; A Zorzano
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

3.  Phosphofructokinase 2 and glycolysis in HT29 human colon adenocarcinoma cell line. Regulation by insulin and phorbol esters.

Authors:  C Denis-Pouxviel; T Gauthier; D Daviaud; J C Murat
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

4.  Insulin-mimetic actions of phorbol ester in cultured adult rat hepatocytes. Lack of phorbol-ester-elicited inhibition of the insulin signal.

Authors:  A Quentmeier; H Daneschmand; H Klein; K Unthan-Fechner; I Probst
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

5.  Stimulation of glycolysis as an activation signal in rat peritoneal macrophages. Effect of glucocorticoids on this process.

Authors:  R Bustos; F Sobrino
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

6.  Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.

Authors:  Sucheta Telang; Brian F Clem; Alden C Klarer; Amy L Clem; John O Trent; Richard Bucala; Jason Chesney
Journal:  J Transl Med       Date:  2012-05-16       Impact factor: 5.531

7.  Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Authors:  Madhav Kishore; Kenneth C P Cheung; Hongmei Fu; Fabrizia Bonacina; Guosu Wang; David Coe; Eleanor J Ward; Alessandra Colamatteo; Maryam Jangani; Andrea Baragetti; Giuseppe Matarese; David M Smith; Robert Haas; Claudio Mauro; David C Wraith; Klaus Okkenhaug; Alberico L Catapano; Veronica De Rosa; Giuseppe D Norata; Federica M Marelli-Berg
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

8.  Activated lymphocytes as a metabolic model for carcinogenesis.

Authors:  Andrew N Macintyre; Jeffrey C Rathmell
Journal:  Cancer Metab       Date:  2013-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.